Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity.

Kudo-Saito, Chie; Garnett, Charlie T; Wansley, Elizabeth K; Schlom, Jeffrey; Hodge, James W

Kudo-Saito, Chie; Garnett, Charlie T; Wansley, Elizabeth K; Schlom, Jeffrey; Hodge, James W.

Affiliation

Kudo-Saito C; Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1750, USA.

Cancer Immunol Immunother ; 56(12): 1897-910, 2007 Dec.

Article in En | MEDLINE | ID: mdl-17503041

Subject(s)

Genetic Therapy/methods; Immunotherapy/methods; Interleukin-2/therapeutic use; Neoplasms/immunology; Neoplasms/therapy; T-Lymphocytes/immunology; Animals; CD4-Positive T-Lymphocytes/metabolism; CD8-Positive T-Lymphocytes/immunology; Cancer Vaccines; Flow Cytometry; Fowlpox/microbiology; Genetic Vectors; Immune System; Interleukin-2/metabolism; Mice; Mice, Inbred C57BL

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: T-Lymphocytes / Genetic Therapy / Interleukin-2 / Immunotherapy / Neoplasms Type of study: Prognostic_studies Limits: Animals Language: En Journal: Cancer Immunol Immunother Journal subject: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Year: 2007 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links